The Hemorrhagic Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemorrhagic Fever. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemorrhagic Fever and features dormant and discontinued products.
GlobalData tracks five drugs in development for Hemorrhagic Fever by five companies/universities/institutes. The top development phase for Hemorrhagic Fever is phase ii with two drugs in that stage. The Hemorrhagic Fever pipeline has four drugs in development by companies and one by universities/ institutes. Some of the companies in the Hemorrhagic Fever pipeline products market are: Bausch Health, Beijing Northland Biotech and Q BioMed.
The key targets in the Hemorrhagic Fever pipeline products market include Angiopoietin 1 Receptor, Inosine Monophosphate Dehydrogenase, and RNA Polymerase.
The key mechanisms of action in the Hemorrhagic Fever pipeline product include Inosine Monophosphate Dehydrogenase Inhibitor with one drug in Phase II. The Hemorrhagic Fever pipeline products include six routes of administration with the top ROA being Inhalational and four key molecule types in the Hemorrhagic Fever pipeline products market including DNA Vaccine, and Fusion Protein.
Hemorrhagic Fever overview
Viral hemorrhagic fevers (VHFs) are a group of diseases caused by several families of viruses. They can affect many organ systems, damage the cardiovascular system, and reduce the body’s ability to function. VHFs are caused by four families of viruses: Ebola, Marburg, Lassa fever, and arenaviridae. Symptoms include fever, fatigue, dizziness, muscle aches, loss of strength, exhaustion, severe headache and muscle and joint pains, sore throat, and loss of appetite. Complete blood count, electrolyte levels, renal function tests, coagulation tests, and urinalysis are useful in diagnosis. No standard therapy is available. Patients receive supportive therapy, which consists of balancing the patient’s fluid and electrolytes, maintaining oxygen status and blood pressure, and treatment for any complications.
For a complete picture of Hemorrhagic Fever’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
